Research Article

Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer

Volume: 46 Number: 2 June 11, 2019
  • Nadiye Akdeniz *
  • Muhammet Ali Kaplan
  • Mehmet Küçüköner
  • Zuhat Urakçı
  • Yasin Sezgin
  • Senar Ebinç
  • Erkan Bilen
  • Oğur Karhan
  • Şahin Laçin
  • Hüseyin Büyükbayram
  • Abdurrahman Işıkdoğan
Dicle Medical Journal Cover
Dicle Medical Journal
PDF Download

Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer

Abstract

Objective: The prognostic value of tumor location in patients with metastatic colorectal cancer (mCRC) was reported by recent analyses in RAS wild-type patients. However, there is no enough specific data regarding prognostic value of primary tumor location in RAS mutated mCRC patients. We aimed to find if there is any relation between tumor prognosis and primary tumor location in patients with RAS mutated mCRC.

Method: This retrospective study included 57 patients with mCRC who were diagnosed and treated in our hospital between January 2011 and December 2017. Characteristics features of the patients were obtained from our institution patient medical records. Patients were included to the present study if KRAS or NRAS mutation was detected in tumor tissues.

Results: Twenty-nine (50.9%) of patients were female and the median age of all patients was 52 (18-80) years. Forty (70.2%) of 57 patients were defined as left side (LS) and 17 (29.8%) of patients were located in the right side (RS). As first line systemic treatment, twenty-five (43.9%) patients had received oxaliplatin-based chemotherapy while 32 (56.1%) patients had received irinotecan-based chemotherapy. Tumor sidedness did not affect on PFS (mPFS, 10.9 months for LS vs 8.1 months for RS, p=0.400) and OS (mOS, 20.9 months for LS vs 20.8 months for RS, p=0.930).The patients who had oxaliplatin based chemotherapy regimens showed better OS rate than irinotecan based regimens (28.7months vs16.3 months, p=0.017, respectively).

Conclusion: Our study results support the thought that claims the sidedness of primary CRC in metastatic setting does not have effect on PFS and OS in patients with RAS mutant mCRC. However, our findings also underline the necessity of studies with larger patient populations and subgroup analyzes to evaluate potential prognostic and molecular features to determine the standart approach to this specific subgroup of the disease.

Keywords

References

  1. 1. Ferlay J, Soerjomataram I, Dikshit R, et all. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: 359–86.
  2. 2. Guinney J, Dienstmann R, Wang X,et all. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21: 1350–6.
  3. 3. Auclin E, Zaanan A, Vernerey D,et all. Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. Ann Oncol Off JEur Soc Med Oncol. 2017; 28: 958–68.
  4. 4. Lie`vre A, Bachet J-B, Boige V, et all. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol Off J Am Soc Clin Oncol. 2008; 26: 374–9.
  5. 5. Rothberg PG, Spandorfer JM, Erisman MD, et all. Evidence that c-myc expression defines two genetically distinct forms of colorectal adenocarcinoma. Br J Cancer. 1985; 52: 629–32.
  6. 6. Meza R, Jeon J, Renehan AG, Luebeck EG. Colorectal cancer incidence trends in the United States and United Kingdom: evidence of right- to left-sided biological gradients with implications for screening. Cancer Res 2010; 70: 5419–29.
  7. 7. Van Cutsem E, Cervantes A, Adam R et all. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–1422.
  8. 8. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol. 2016; 34: 3504.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Authors

Hüseyin Büyükbayram This is me
0000-0002-7168-1507

Abdurrahman Işıkdoğan This is me
0000-0002-7451-7286

Publication Date

June 11, 2019

Submission Date

January 11, 2019

Acceptance Date

March 4, 2019

Published in Issue

Year 2019 Volume: 46 Number: 2

DOI

https://doi.org/10.5798/dicletip.539998

IZ

https://izlik.org/JA49TM43GA

Cite

RIS / Bibtex
APA
Akdeniz, N., Kaplan, M. A., Küçüköner, M., Urakçı, Z., Sezgin, Y., Ebinç, S., Bilen, E., Karhan, O., Laçin, Ş., Büyükbayram, H., & Işıkdoğan, A. (2019). Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer. Dicle Medical Journal, 46(2), 247-253. https://doi.org/10.5798/dicletip.539998
AMA
1.Akdeniz N, Kaplan MA, Küçüköner M, et al. Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer. Dicle Medical Journal. 2019;46(2):247-253. doi:10.5798/dicletip.539998
Chicago
Akdeniz, Nadiye, Muhammet Ali Kaplan, Mehmet Küçüköner, et al. 2019. “Prognostic Importance of Primary Tumor Location in RAS Mutant Metastatic Colorectal Cancer”. Dicle Medical Journal 46 (2): 247-53. https://doi.org/10.5798/dicletip.539998.
EndNote
Akdeniz N, Kaplan MA, Küçüköner M, Urakçı Z, Sezgin Y, Ebinç S, Bilen E, Karhan O, Laçin Ş, Büyükbayram H, Işıkdoğan A (June 1, 2019) Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer. Dicle Medical Journal 46 2 247–253.
IEEE
[1]N. Akdeniz et al., “Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer”, Dicle Medical Journal, vol. 46, no. 2, pp. 247–253, June 2019, doi: 10.5798/dicletip.539998.
ISNAD
Akdeniz, Nadiye - Kaplan, Muhammet Ali - Küçüköner, Mehmet - Urakçı, Zuhat - Sezgin, Yasin - Ebinç, Senar - Bilen, Erkan et al. “Prognostic Importance of Primary Tumor Location in RAS Mutant Metastatic Colorectal Cancer”. Dicle Medical Journal 46/2 (June 1, 2019): 247-253. https://doi.org/10.5798/dicletip.539998.
JAMA
1.Akdeniz N, Kaplan MA, Küçüköner M, Urakçı Z, Sezgin Y, Ebinç S, Bilen E, Karhan O, Laçin Ş, Büyükbayram H, Işıkdoğan A. Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer. Dicle Medical Journal. 2019;46:247–253.
MLA
Akdeniz, Nadiye, et al. “Prognostic Importance of Primary Tumor Location in RAS Mutant Metastatic Colorectal Cancer”. Dicle Medical Journal, vol. 46, no. 2, June 2019, pp. 247-53, doi:10.5798/dicletip.539998.
Vancouver
1.Nadiye Akdeniz, Muhammet Ali Kaplan, Mehmet Küçüköner, Zuhat Urakçı, Yasin Sezgin, Senar Ebinç, Erkan Bilen, Oğur Karhan, Şahin Laçin, Hüseyin Büyükbayram, Abdurrahman Işıkdoğan. Prognostic importance of primary tumor location in RAS mutant metastatic colorectal cancer. Dicle Medical Journal. 2019 Jun. 1;46(2):247-53. doi:10.5798/dicletip.539998

Cited By

Decreased CDX2 Expression Adversely Effect On Prognosis Of Patients With Colorectal Cancer

Dicle Tıp Dergisi

https://doi.org/10.5798/dicletip.706005